| Objective To observe the effect of parathyroid hormone (1-34, PTH) combined with ibandronate sodium on serious postmenopausal osteoporosis. Methods 98 patients with serious postmenopausal osteoporosis and bone pain were randomly divided into treatment group and control group. The treatment group was treated with PTH combined with ibandronate, and the control group was treated with ibandronate sodium for 12 months. The changes of bone mineral density and serum bone metabolic index were measured before and after treatment. Results In both groups, bone density of lumbar vertebrae L1-4, proximal femur, left femoral neck and Ward triangle increased significantly after 6 months of intervention, and further increased after 12 months, with greater effects in the combined treatment group than in the control group (P<0.05). After 12 months of intervention, the levels of serum alkaline phosphatase (ALP), serum type I collagen C-terminal peptide (s - CTX), serum anti-tartrate acid phosphatase - 5b (TRACP -5b) and serum osteocalcin (OC) changed significantly, and the changes in ALP, s-CTX, BAP, OC and TRACP-5b were greater in the treatment group compared with that of the control group (P<0.05). There were no significant differences between the two groups in the concentrations of serum Ca and phosphorus (P) before and after treatment (P?0.05). Conclusion PTH combined with ibandronate can effectively protect hip and lumbar vertebrae bone mineral density and improve bone metabolism in serious postmenopausal osteoporosis. |